medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 10

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (10)

Typification of high-risk human papilomavirus serotypes

Soto-Fuenzalida GA, Hernández-Hernández JA, López-Sánchez RC, Aguayo-Millán CD, Villela-Martínez LM, Espino-Rodríguez M, Niño-Parra VE, Ortiz-López R

Language: Spanish
References: 25
Page: 659-666
PDF size: 210.08 Kb.


ABSTRACT

Objective: To identify the most frequent serotypes of human papillomavirus through random testing of patients previously diagnosed with cervical cancer.
Materials and Methods: A prospective, observational study carried out in patients with cervical dysplasia, treated at the High Specialty Regional Maternal and Child Hospital of Nuevo León, Monterrey. Inclusion criteria: patients over 18 years of age, who attended the Dysplasia Clinic of the High Specialty Regional Maternal and Child Hospital for gynecological follow-up and control, with an abnormal result in the Papanicolaou test, confirmed by histopathology, by means of colposcopy-directed biopsy. Before the procedures (cervical cytology), Exclusion criteria: women with total hysterectomy due to indications of benign disease, without a history of intracervical neoplasia; older than 70 years after 3 negative cervical cytology in the previous decade; patients who received chemotherapy, radiotherapy or other pharmacological treatments and who received medical check-ups during their menstrual cycle. Descriptive statistics were used for data analysis.
Results: 30 patients were registered. The most frequent classification of cervical neoplasia was: CIN1 (n = 15), CIN2 (n = 9) and CIN3 (n = 6). All the patients analyzed had at least one high-risk HPV serotype. The most frequently identified serotypes were 31 and 33 (n = 18 of 30). 6 or more HPV serotypes were found in 18 patients. Of 15 patients with high-grade lesions, 8 had the association of serotypes 31 and 33, and in 6 an isolated serotype was identified (16 and 51).
Conclusions: The most frequently identified serotypes were 31 and 33. Unfortunately, the nonavalent vaccine that protects against the most frequent serotypes of HPV is not available in Latin America.


REFERENCES

  1. Hoffman L, et al. Williams Gynecology. 3rd ed. New York: McGraw-Hill, 2016.

  2. Gray FD, et al. Internal Medicine. JAMA 1980;243(21):2190- 2191. doi:10.1001/jama.1980.03300470050029.

  3. World Health Organization. Globocan 2018. Globocan 2018 (2018). https://gco.iarc.fr/today/data/factsheets/ populations/900-world-fact-sheets.pdf

  4. National Institutes of Health Consensus Development Conference Statement on Cervical CancerApril 1-3, 1996. Gynecol Oncol 1997;66(3):351-61. doi: 10.1006/ gyno.1997.4849.

  5. Hidalgo-Martínez AC. El cáncer cérvico-uterino, su impacto en México y el porqué no funciona el programa nacional de detección oportuna. Rev Biomed 2006;17(1). doi: http:// doi.org/10.32776/revbiomed.v17i1.441.

  6. Consenso Nacional Intersociedades sobre Cáncer de Cuello Uterino Agosto 2015. Rev Argentina Radiol 2017;81(2):157- 177. doi:10.1016/j.rard.2016.11.001.

  7. Warren JB, et al. Cervical Cancer Screening and Updated Pap Guidelines. Primary Care: Clinics in Office Practice 2009;36(1):131-149. doi: http://doi.org/10.1016/j. pop.2008.10.008

  8. Herrera Y, et al. Historia de la evolución de las pruebas de tamizaje en el cáncer cervicouterino. Rev Med Inst Mex Seg Soc 2015;53;(6):670-7. https://www.medigraphic.com/ pdfs/imss/im-2015/im156b.pdf

  9. Tergas AI, et al. Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer. Gynecol Oncol 2013;130(3):421-425. doi: 10.1016/j. ygyno.2013.05.037.

  10. Fajardo-Ramírez OR, et al. Prevalence and 3-year persistence of human papillomavirus serotypes in asymptomatic patients in northern Mexico. Int J Gynecol Obstet 2016;136(1):40-46. doi: 10.1002/ijgo.12009.

  11. Gallegos-Bolaños J, et al. High prevalence of co-infection between human papillomavirus (HPV) 51 and 52 in Mexican population. BMC Cancer 2017;17(1):531. doi: 10.1186/ s12885-017-3519-7.

  12. López-Soberón A, et al. Cáncer cérvicouterino y el virus del papiloma humano: La historia que no termina. Cancerología (2006). http://incan-mexico.org/revistainvestiga/ elementos/documentosPortada/1172193073.pdf

  13. Handa VL, et al. Te Linde. Ginecología Quirúrgica. 10ª ed. Buenos Aires: Editorial Médica Panamericana, 2008.

  14. Muñoz N, et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348(6):518-27. doi: 10.1056/NEJMoa021641.

  15. Serman, F. Cancer cervicouterino: epidemiologia, historia natural y rol del virus papiloma humano: perspectivas en prevencion y tratamiento. Rev Chil Obstet Ginecol 2009;67(4). doi: http://dx.doi.org/10.4067/S0717- 75262002000400011

  16. Kliegman RM, et al. Nelson Textbook. 20th ed; 2016, 129. doi: https://doi.org/10.1016/B978-1-4377-0755-7.00710-7

  17. Barbieri D, et al. Comparison of HPV sign Genotyping Test with INNO-LiPA HPV Genotyping Extra assay on histologic and cytologic cervical specimens. Diagn Microbiol Infect Dis 2012;74(1):43-48. doi: 10.1016/j.diagmicrobio.2012.05.014.

  18. Chase DM, et al. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol 2009;200(5):472- 480. doi: 10.1016/j.ajog.2008.12.025.

  19. Lizano-soberón M, et al. Infección por virus del papiloma humano: Epidemiología, historia natural y carcinogénesis. Cancerol 2009;4:205-216. http://incan-mexico.org/revistainvestiga/ elementos/documentosPortada/1272302572.pdf

  20. Whitlock EP, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(10):687-97. DOI: 10.7326/0003- 4819-155-10-201111150-00376

  21. Huh WK, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 2017;390(10108):2143-2159. doi: 10.1016/ S0140-6736(17)31821-4.

  22. Flores-Medina S, et al. Genotipificación del virus del papiloma humano en mujeres que asisten a un hospital gineco-obstétrico de tercer nivel de la Ciudad de México. Rev Chil Obstet Ginecol 2016;81(5). doi: 10.4067/S0717- 75262016000500006.

  23. Navarro-Vidal E, et al. Prevalence of Human Papillomavirus Genotypes in Women from Cozumel, Mexico. Asian Pac J Cancer Prev 2018;19(9):2422. doi: 10.22034/ APJCP.2018.19.9.2417.

  24. Sánchez-Anguiano LF, et al. Human papillomavirus infections in women seeking cervical Papanicolaou cytology of Durango, Mexico: Prevalence and genotypes. BMC Infect Dis 2006;6:27. doi: 10.1186/1471-2334-6-27.

  25. Ortega-Cervantes L, et al. Human papilloma virus genotypes in women from Nayarit, Mexico, with squamous intraepithelial lesions and cervical cancer. Int J Health Sci (Qassim) 2016;10(3):327-38. https://www.ncbi.nlm.nih. gov/pmc/articles/PMC5003576/




2020     |     www.medigraphic.com